PAVmed Inc. (PAVM) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, PAVmed Inc. (NASDAQ: PAVM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.95 (-1.01% 1D, market cap $15.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PAVM ranks #870 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), PAVM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MODD (Modular Medical Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, PAVM leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).
Per PAVM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001624326), PAVmed Inc. generated $71.0K in revenue (-97.6% YoY), -$3.8M in net income, and -$5.2M in free cash flow against $38.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While PAVM currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.44) and Max Pain ($2.05) forces dealer call-delta covering toward $29.86.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
PAVmed Inc. (PAVM) slipped -1.01% to $1.95, trading at 2% of its 52-week range ($1.84 – $28.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a busine
RingCentral surged 15% after beating Q3 estimates and raising FY26 guidance; XXII, LABT and HUBC led premarket gainers, while LNAI fell.
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has begun receivin
On September 22, Lucid announced that it would begin submitting Medicare claims for EsoGuard tests performed at one of its two CLIA-certified laboratories. Shortly thereafter, the Company began receiving payments on
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PAVM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PAVM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, PAVmed Inc. (PAVM) ranks #870 by composite RQD confidence (28/100, grade E) and #852 by equity capitalization ($15.6M). Within this direct 5-issuer industry benchmark cohort, PAVM leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with PAVM at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PAVM
ACTIVE
PAVmed Inc. | E | 28/100 | — | -30.0% | -35.0% | -1.01% | $15.6M | Benchmark Subject |
| MODD Modular Medical Inc. | E | 33/100 | — | — | -35.0% | 0.00% | $16.3M | /modd-vs-pavm → |
| RVP Retractable Technologies Inc. | E | 31/100 | — | 0.1% | -23.3% | -1.96% | $16.9M | /rvp-vs-pavm → |
| CTSO Cytosorbents Corporation | E | 22/100 | — | 71.5% | -35.0% | +3.18% | $14.3M | /ctso-vs-pavm → |
| GUTS Fractyl Health Inc. | E | 34/100 | — | — | -35.0% | -1.51% | $13.0M | /guts-vs-pavm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), PAVmed Inc. (PAVM) reported GAAP revenue of $71.0K (-97.6% vs. FY2024 revenue of $3.0M , and -97.1% cumulative change since FY2023) , GAAP net income of -$3.8M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+84.4% YoY). On the balance sheet, PAVM closed FY2025 with $38.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $71.0K | -$3.8M | -$5.2M | -$5.2M | $38.8M | — |
| FY2024 (FY) | 2024-12-31 | $3.0M | $32.0M | -$33.6M | -$33.6M | $30.7M | — |
| FY2023 (FY) | 2023-12-31 | $2.5M | -$66.3M | -$52.0M | -$52.0M | — | — |
As of 2026-11-03, PAVmed Inc. (NASDAQ: PAVM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.95 (-1.01% 1D, market cap $15.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PAVM ranks #870 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), PAVM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MODD (Modular Medical Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, PAVM leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).
Per PAVM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001624326), PAVmed Inc. generated $71.0K in revenue (-97.6% YoY), -$3.8M in net income, and -$5.2M in free cash flow against $38.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PAVM last traded at $1.95 (-1.01% on volume of 6,618 shares), positioning the stock -43.31% below its 50-day simple moving average ($3.44) and -70.05% below its 200-day simple moving average ($6.51). Across its 52-week range of $1.84 to $28.44, PAVM sits at the 0.4% percentile with a 14-day RSI of 27.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.71 to $2.19).
Why PAVM Stock slipped -1.01% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, PAVM scores 28 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). Every pillar sits in the lower half of its range, with the two weakest being Whale 13F Flow and Insider Conviction. For a prospective investor, the upside case rests on a stock priced at $1.97 with a 52-week range of $1.84 to $28.44, which implies the market has already priced in severe deterioration. However, the cash-engine pillar shows negative returns on invested capital and no free-cash-flow yield, meaning the business is not currently generating a return that would support a valuation rebound on fundamentals. The forensic pillar's Piotroski F-Score of 1 out of 9 signals weak financial health across the nine tests. The institutional and insider pillars do not offer a counterweight, as both score 3 of 20. The composite profile therefore points to elevated risk and limited near-term fundamental support, which is the analytical basis for the rating's avoid verdict.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.1M | $-21.8M | $-3.8M | N/A | $-5.2M | $1.5M | N/A |
| FY 2024 | $3.0M | $-44.5M | $32.0M | N/A | $-33.6M | $1.2M | N/A |
| FY 2023 | $2.5M | $-68.8M | $-66.3M | N/A | $-52.0M | N/A | N/A |
Per the SEC financials, gross margin is -30%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Revenue declined from $3.0M in FY 2024 to $0.1M in FY 2025, while operating losses narrowed from $-44.5M to $-21.8M. The FY 2024 net income of $32.0M contrasts sharply with its operating loss and should be treated as an anomaly the source data does not explain. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1 of 9 per the Roarable RQD rating, with Debt/Equity at 0.5. Cash stood at $1.5M at FY 2025 year-end.
Per the recent news wire, the most significant item is a $15 million Series C preferred stock raise by subsidiary Lucid Diagnostics, reported across several outlets (Investing.com, TradingView, and a GREEN catalyst flag). Financing of this kind supports near-term liquidity but adds dilution and preferred claims ahead of common holders. A Q3 2026 business update call is scheduled for November 13, 2026 (MARKET WIRE, YELLOW). Several items are market-wire commentary on price levels, including references to support near $2.29 and a price near $2.41, which are not fundamental catalysts. Benzinga pre-market and after-market health care roundups reference PAVM among moving stocks, indicating news-driven volatility rather than a fundamental change. The Butterfly supply-chain graph reports no supply chain links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for PAVmed Inc. (PAVM) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering PAVmed Inc. (PAVM) market action, institutional positioning, and fundamental catalysts.
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a busine
RingCentral surged 15% after beating Q3 estimates and raising FY26 guidance; XXII, LABT and HUBC led premarket gainers, while LNAI fell.
Welcome to the PAVM (PAVmed Inc.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PAVM, but look at what you are paying: current EV/EBITDA multiples with -30.0% gross margins. Unless PAVmed Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PAVM, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $1.97 (52-wk range $1.84 - $28.44), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).